146 related articles for article (PubMed ID: 18070466)
1. [The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting].
Han YL; Li CY; Li Y; Kang J; Yan CH
Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Sep; 35(9):788-92. PubMed ID: 18070466
[TBL] [Abstract][Full Text] [Related]
2. [The effects of post coronary stenting triple antiplatelet therapies on platelet functions].
Han YL; Su QF; Li Y; Kang J; Yan CH; Wang SL
Zhonghua Nei Ke Za Zhi; 2006 Aug; 45(8):635-8. PubMed ID: 17074146
[TBL] [Abstract][Full Text] [Related]
3. [Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina].
Shen J; Zhang RY; Zhang Q
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Sep; 36(9):807-11. PubMed ID: 19102862
[TBL] [Abstract][Full Text] [Related]
4. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
Wenaweser P; Windecker S; Billinger M; Cook S; Togni M; Meier B; Haeberli A; Hess OM
Am J Cardiol; 2007 Feb; 99(3):353-6. PubMed ID: 17261397
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Mitsios JV; Papathanasiou AI; Rodis FI; Elisaf M; Goudevenos JA; Tselepis AD
Circulation; 2004 Mar; 109(11):1335-8. PubMed ID: 15023882
[TBL] [Abstract][Full Text] [Related]
6. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Park Y; Jeong YH; Tantry US; Ahn JH; Kwon TJ; Park JR; Hwang SJ; Gho EH; Bliden KP; Kwak CH; Hwang JY; Kim S; Gurbel PA
Eur Heart J; 2012 Sep; 33(17):2151-62. PubMed ID: 22507978
[TBL] [Abstract][Full Text] [Related]
7. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
[TBL] [Abstract][Full Text] [Related]
8. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.
Trenk D; Hochholzer W; Frundi D; Stratz C; Valina CM; Bestehorn HP; Büttner HJ; Neumann FJ
Thromb Haemost; 2008 Jan; 99(1):174-81. PubMed ID: 18217151
[TBL] [Abstract][Full Text] [Related]
9. Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome.
Hong SJ; Park JY; Kim KA; Ahn CM; Park JS; Kim YH; Shim WJ; Park SM; Lim DS
Circ J; 2009 Jun; 73(6):1111-8. PubMed ID: 19372620
[TBL] [Abstract][Full Text] [Related]
10. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Saw J; Steinhubl SR; Berger PB; Kereiakes DJ; Serebruany VL; Brennan D; Topol EJ;
Circulation; 2003 Aug; 108(8):921-4. PubMed ID: 12925453
[TBL] [Abstract][Full Text] [Related]
11. [Influence of statins on the antiplatelet effect of clopidogrel and on cardiovascular outcome in patients after coronary intervention].
Zürn CS; Geisler T; Paterok M; Gawaz M
Dtsch Med Wochenschr; 2008 Apr; 133(16):817-22. PubMed ID: 18398789
[TBL] [Abstract][Full Text] [Related]
12. Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation).
Poyet R; Cuisset T; Frere C; Quilici J; Gaborit B; Moro PJ; Camoin L; Morange PE; Bonnet JL; Alessi MC
Thromb Res; 2010 Nov; 126(5):e397-9. PubMed ID: 20825983
[No Abstract] [Full Text] [Related]
13. Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
Malmström RE; Ostergren J; Jørgensen L; Hjemdahl P;
J Intern Med; 2009 Nov; 266(5):457-66. PubMed ID: 19549094
[TBL] [Abstract][Full Text] [Related]
14. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
Tetik S; Ak K; Isbir S; Eksioglu-Demiralp E; Arsan S; Iqbal O; Yardimci T
Clin Appl Thromb Hemost; 2010 Apr; 16(2):189-98. PubMed ID: 19703819
[TBL] [Abstract][Full Text] [Related]
15. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
Smith SM; Judge HM; Peters G; Storey RF
Platelets; 2004 Dec; 15(8):465-74. PubMed ID: 15763887
[TBL] [Abstract][Full Text] [Related]
16. [Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting: a randomized controlled trial].
Han YL; Zhang ZL; Li Y; Wang SL; Jing QM; Wang ZL; Wang DM
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2240-4. PubMed ID: 20095333
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting.
Gorchakova O; von Beckerath N; Gawaz M; Mocz A; Joost A; Schömig A; Kastrati A
Eur Heart J; 2004 Nov; 25(21):1898-902. PubMed ID: 15522468
[TBL] [Abstract][Full Text] [Related]
18. Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation.
Serrano Júnior CV; Soeiro Ade M; Araújo LF; Jabot B; Rached F; Orii NM; Nicolau JC; Duarte AJ; Ramires JA
Arq Bras Cardiol; 2010 Sep; 95(3):321-7. PubMed ID: 20721515
[TBL] [Abstract][Full Text] [Related]
19. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
Mitsios JV; Papathanasiou AI; Elisaf M; Goudevenos JA; Tselepis AD
Platelets; 2005 Aug; 16(5):287-92. PubMed ID: 16011979
[TBL] [Abstract][Full Text] [Related]
20. [Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin].
Pokrovskaia EV; Vaulin NA; Gratsianskiĭ NA; Averkov OV; Deev AD
Kardiologiia; 2003; 43(1):7-18. PubMed ID: 12891281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
